Leukemia | Norton Healthcare

Indication: Leukemia

A Phase I/II open label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of ONO-7475 in patients with acute leukemias or myelodysplastic syndromes

Sub-indication: Hematological Malignancies

Study Type: Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: Sponsor: ONO Pharmaceutical Co., Ltd.

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.